Gadopiclenol (Elucirem): A New Gadolinium Based Contrast Agent With High Relaxivity for Increased Contrast and Improved Differentiation of Clinically Significant Prostate Cancer on Contrast Enhanced MRI: A Prospective Study.
Latest Information Update: 29 Sep 2024
At a glance
- Drugs Gadopiclenol (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
Most Recent Events
- 19 Sep 2024 Status changed from not yet recruiting to suspended because the Principal Investigator has been transferred to a new institution, therefore, the record/study is getting transferred.
- 31 Jan 2024 New trial record